In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


High Hopes For Merck/AiCuris Late-Stage CMV Candidate Despite Chimerix Failure

This article was originally published in Scrip

Executive Summary

Chimerix Inc.'s dramatic Phase III flop of its oral antiviral brincidofovir in human cytomegalovirus (HCMV) was not a disappointment to everyone. Merck & Co. Inc. and its little-known German partner AiCuris, which have Phase III data due later this year on their oral product letermovir (AIC246), suddenly found themselves in the lead with a very promising next-generation candidate for the treatment of HCMV.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts